Have your own idea? Try our Stock Screener
U.K. (FTSE) Biotech Industry Analysis
UpdatedApr 18, 2026
DataAggregated Company Financials
Companies21
- 7D5.0%
- 3M-13.1%
- 1Y41.8%
- YTDn/a
The Biotech industry is up 4.7% in the last week, with Oxford Biomedica up 13%. Meanwhile, Hemogenyx Pharmaceuticals actually underperformed within the industry, shrinking 6.3% in the last week. This means that the industry has gained 41% over the past year. As for the next few years, earnings are expected to grow by 11% per annum.
Industry Valuation and Performance
Has the U.K. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 18 Apr 2026 | UK£3.3b | UK£889.7m | UK£11.5m | 12.6x | 289.3x | 3.7x |
| Mon, 16 Mar 2026 | UK£3.3b | UK£875.5m | -UK£4,003,467.62 | 8.7x | -814.7x | 3.7x |
| Wed, 11 Feb 2026 | UK£3.9b | UK£876.0m | -UK£28,421,605.30 | 10.3x | -135.8x | 4.4x |
| Fri, 09 Jan 2026 | UK£3.4b | UK£876.1m | -UK£28,357,607.42 | 10.7x | -120x | 3.9x |
| Sun, 07 Dec 2025 | UK£3.2b | UK£897.0m | -UK£29,164,475.25 | 10.2x | -109.9x | 3.6x |
| Tue, 04 Nov 2025 | UK£3.2b | UK£886.6m | -UK£43,036,428.51 | 11.6x | -75.4x | 3.7x |
| Thu, 02 Oct 2025 | UK£3.2b | UK£878.6m | -UK£41,123,604.85 | 16.3x | -77.6x | 3.6x |
| Sat, 30 Aug 2025 | UK£3.4b | UK£855.7m | -UK£107,501,260.52 | 12.4x | -31.9x | 4x |
| Mon, 28 Jul 2025 | UK£3.0b | UK£854.6m | -UK£103,167,115.33 | 13.4x | -29.4x | 3.5x |
| Wed, 25 Jun 2025 | UK£2.5b | UK£857.0m | -UK£104,263,991.00 | 12.7x | -23.9x | 2.9x |
| Fri, 23 May 2025 | UK£2.4b | UK£879.3m | -UK£91,881,151.42 | 13.6x | -25.9x | 2.7x |
| Sun, 20 Apr 2025 | UK£2.1b | UK£876.4m | -UK£169,598,336.21 | 17x | -12.4x | 2.4x |
| Tue, 18 Mar 2025 | UK£2.4b | UK£844.0m | -UK£277,000,446.53 | 18.4x | -8.7x | 2.9x |
| Thu, 13 Feb 2025 | UK£2.7b | UK£842.1m | -UK£295,314,390.08 | 85.9x | -9.1x | 3.2x |
| Sat, 11 Jan 2025 | UK£2.5b | UK£842.6m | -UK£296,893,058.52 | 71.9x | -8.4x | 3x |
| Mon, 09 Dec 2024 | UK£2.7b | UK£841.4m | -UK£293,453,317.58 | 80.4x | -9.1x | 3.2x |
| Wed, 06 Nov 2024 | UK£2.9b | UK£840.1m | -UK£292,366,884.42 | 94.1x | -9.8x | 3.4x |
| Fri, 04 Oct 2024 | UK£2.9b | UK£840.1m | -UK£295,405,284.11 | 97.3x | -9.8x | 3.5x |
| Sun, 01 Sep 2024 | UK£2.8b | UK£834.4m | -UK£289,119,256.88 | 30.4x | -9.8x | 3.4x |
| Tue, 30 Jul 2024 | UK£2.7b | UK£838.0m | -UK£257,225,327.28 | 30.4x | -10.5x | 3.2x |
| Thu, 27 Jun 2024 | UK£2.5b | UK£835.8m | -UK£273,709,418.56 | 29.8x | -9.1x | 3x |
| Sat, 25 May 2024 | UK£3.0b | UK£836.7m | -UK£287,505,558.48 | 31.1x | -10.4x | 3.6x |
| Mon, 22 Apr 2024 | UK£3.0b | UK£903.1m | -UK£201,990,058.31 | 28.8x | -14.9x | 3.3x |
| Wed, 20 Mar 2024 | UK£3.1b | UK£897.7m | -UK£203,638,078.85 | 33.7x | -15x | 3.4x |
| Fri, 16 Feb 2024 | UK£3.1b | UK£913.4m | -UK£198,102,426.30 | 30.4x | -15.7x | 3.4x |
| Sun, 14 Jan 2024 | UK£6.3b | UK£1.3b | -UK£245,123,674.00 | 37.6x | -25.9x | 5x |
| Tue, 12 Dec 2023 | UK£6.2b | UK£1.3b | -UK£245,936,057.00 | 36.4x | -25.1x | 4.9x |
| Thu, 09 Nov 2023 | UK£6.4b | UK£1.3b | -UK£243,295,328.00 | 38.1x | -26.2x | 5x |
| Sat, 07 Oct 2023 | UK£6.5b | UK£1.3b | -UK£250,796,637.00 | 37.9x | -26.1x | 5.1x |
| Mon, 04 Sep 2023 | UK£6.7b | UK£1.3b | -UK£205,920,114.00 | 23.6x | -32.4x | 5.3x |
| Wed, 02 Aug 2023 | UK£6.9b | UK£1.3b | -UK£209,123,684.00 | 23.6x | -33x | 5.5x |
| Fri, 30 Jun 2023 | UK£6.7b | UK£1.3b | -UK£209,507,519.00 | 23.9x | -31.8x | 5.3x |
| Sun, 28 May 2023 | UK£7.0b | UK£1.3b | -UK£205,061,887.00 | 23.3x | -34x | 5.5x |
| Tue, 25 Apr 2023 | UK£7.2b | UK£1.2b | -UK£156,280,796.00 | 23.6x | -45.8x | 5.8x |
Price to Earnings Ratio
-45.8x
Current Industry PE
- Investors are optimistic on the British Biotechnology industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 287x which is higher than its 3-year average PE of -32.6x.
- The industry is trading close to its 3-year average PS ratio of 3.9x.
Past Earnings Growth
- Total earnings for the Biotechnology industry have gone up over the last three years and the industry is now profitable.
- Revenues have declined 11% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, profits have been increasing.
Industry Comparison
How does U.K. Biotech compare with similar industries?
| GB Market | 1.05% | |
| Healthcare | -0.63% | |
| Biotech | 4.99% | |
| Biotech | 4.99% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| OXB Oxford Biomedica | UK£6.41 | 13.3% +UK£90.7m | 114.4% | PS4.6x | |
| GNS Genus | UK£26.44 | 2.6% +UK£45.5m | 63.4% | PE37.2x | |
| FARN Faron Pharmaceuticals Oy | UK£0.44 | 1.1% +UK£37.4m | -79.0% | PE-3.7x | |
| AVCT Avacta Group | UK£0.77 | 10.0% +UK£31.7m | 120.0% | PS3088.7x | |
| PRTC PureTech Health | UK£1.32 | 9.1% +UK£26.8m | 7.3% | PE8.6x |